TopMarketGainers

$SLS TOP WATCHLIST STOCK, ON TUMOR DATA

Long
NASDAQ:SLS   SELLAS LIFE SCIENCES GROUP INC
POSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES.

SHORT INTEREST 13.2%
AVERAGE ANALYSTS PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S ( GPS ), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has a Phase 3 clinical trial planned (pending funding availability) for GPS in acute myeloid leukemia ( AML ) and is also studying GPS in combination with pembrolizumab in multiple indications. SELLAS has received Orphan Drug designations for GPS from the FDA and the European Medicines Agency ( EMA ) for AML , malignant pleural mesothelioma ( MPM ), and multiple myeloma (MM); GPS has also received Fast Track designation for AML , MPM and MM from the FDA. SELLAS’ second product candidate, NPS , is a HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NPS has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following standard of care.
Do you want to GAIN an Edge on Wall Street? 🤑💰📈

1) Sign Up for Free @ http://www.TopMarketGainers.com

2) Follow our Telegram Channel @ https://t.me/TopMarketGainers

3) Join our LIVE CHAT on our Discord @ https://discord.gg/bGANmgy

Comments

Home Stock Screener Forex Screener Crypto Screener Economic Calendar About Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out